Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7837398 | 0.92 | ALDH1A1 (0.36) | MAPK1CYP19A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL7837576 | 0.88 | TBXA2R (0.32) | CYP19A1CYP1A2CYP2C19 | |
| SCHEMBL7848884 | 0.85 | CNR2 (0.35) | — | |
| SCHEMBL7848868 | 0.82 | SMN1; SMN2 (0.33) | MAPK1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7837753 | 0.82 | CYP19A1 (0.31) | MAPK1CYP19A1 | |
| SCHEMBL7845258 | 0.79 | L3MBTL1 (0.41) | MAPK1 | |
| SCHEMBL7838193 | 0.77 | ALDH1A1 (0.41) | MAPK1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7849223 | 0.75 | SLC10A2 (0.35) | MAPK1CYP19A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL7846313 | 0.74 | ALDH1A1 (0.39) | MAPK1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7850479 | 0.73 | NPSR1 (0.36) | MAPK1CYP19A1CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1155007-A2 | 1,2-BENZOTHIAZEPINES FOR THE TREATMENT OF HYPERLIPIDEMIC DISEASES | G.D. Searle LLC (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047568-A2 | 1,2-BENZOTHIAZEPINES FOR THE TREATMENT OF HYPERLIPIDEMIC DISEASES | G.D. SEARLE LLC (US) | 2000-08-17 | — | — | WO | disclosed |